Acquisition Context Questcor is now part of Mallinckrodt, operating within the Autoimmune and Rare Diseases segment. This integration presents cross-sell opportunities to Mallinckrodt’s existing customer base in neurology, nephrology, rheumatology, and pulmonology, with potential to expand reach for Questcor’s autoimmune therapies.

Specialty Focus Mallinckrodt emphasizes high-value specialty pharmaceuticals and imaging. Sales opportunities exist to positionQuestcor’s treatments alongside Mallinckrodt’s diagnostics, contrast media, and nuclear medicine offerings, enabling bundled solutions for complex autoimmune and inflammatory disorders.

Growth Ambition The company’s stated goal is above-market growth through accelerated product development. This creates avenues for co-development discussions, strategic partnerships, and early access programs to bring novel autoimmune therapies to market faster.

Regulatory & Risk Landscape Recent legal actions and bankruptcy-related headlines suggest heightened regulatory and compliance considerations. A sales strategy should emphasize risk mitigation, robust post-market support, and clear leverage points for customers seeking stable supply and reliable compliance.

Digital & Analytics Readiness Mallinckrodt’s tech stack includes SAP, Workday, Tableau, and data platforms. Leverage these to propose data-driven services, real-world evidence collaborations, and integrated reporting that demonstrate value and outcomes to health systems and payers.